Fulgent Genetics PE Ratio 2015-2026 | FLGT
Current and historical p/e ratio for Fulgent Genetics (FLGT) from 2015 to 2026. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Fulgent Genetics PE ratio as of September 14, 2026 is 0.00.
| Fulgent Genetics PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2026-09-15 | 21.28 | 0.00 | |
| 2026-06-30 | 20.52 | $-2.83 | 0.00 |
| 2026-03-31 | 15.90 | $-2.40 | 0.00 |
| 2025-12-31 | 26.27 | $-1.97 | 0.00 |
| 2025-09-30 | 22.60 | $-1.39 | 0.00 |
| 2025-06-30 | 19.88 | $-1.66 | 0.00 |
| 2025-03-31 | 16.90 | $-1.33 | 0.00 |
| 2024-12-31 | 18.47 | $-1.41 | 0.00 |
| 2024-09-30 | 21.73 | $-5.51 | 0.00 |
| 2024-06-30 | 19.62 | $-5.47 | 0.00 |
| 2024-03-31 | 21.70 | $-5.56 | 0.00 |
| 2023-12-31 | 28.91 | $-5.63 | 0.00 |
| 2023-09-30 | 26.74 | $-2.07 | 0.00 |
| 2023-06-30 | 37.03 | $-1.57 | 0.00 |
| 2023-03-31 | 31.22 | $-0.82 | 0.00 |
| 2022-12-31 | 29.78 | $4.63 | 6.43 |
| 2022-09-30 | 38.12 | $8.70 | 4.38 |
| 2022-06-30 | 54.53 | $12.57 | 4.34 |
| 2022-03-31 | 62.41 | $14.79 | 4.22 |
| 2021-12-31 | 100.59 | $16.38 | 6.14 |
| 2021-09-30 | 89.95 | $19.92 | 4.52 |
| 2021-06-30 | 92.23 | $17.97 | 5.13 |
| 2021-03-31 | 96.62 | $15.52 | 6.23 |
| 2020-12-31 | 52.10 | $8.91 | 5.85 |
| 2020-09-30 | 40.04 | $2.01 | 19.92 |
| 2020-06-30 | 16.00 | $0.11 | 145.45 |
| 2020-03-31 | 10.76 | $-0.01 | 0.00 |
| 2019-12-31 | 12.90 | $-0.02 | 0.00 |
| 2019-09-30 | 10.39 | $-0.11 | 0.00 |
| 2019-06-30 | 6.68 | $-0.22 | 0.00 |
| 2019-03-31 | 5.95 | $-0.30 | 0.00 |
| 2018-12-31 | 3.17 | $-0.31 | 0.00 |
| 2018-09-30 | 3.93 | $-0.29 | 0.00 |
| 2018-06-30 | 4.14 | $-0.32 | 0.00 |
| 2018-03-31 | 4.00 | $-0.26 | 0.00 |
| 2017-12-31 | 4.38 | $-0.14 | 0.00 |
| 2017-09-30 | 4.79 | $0.10 | 47.90 |
| 2017-06-30 | 6.39 | $-0.28 | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.568B | $0.323B |
| Fulgent Genetics, Inc. provides genetic testing services to physicians with clinically actionable diagnostic information. The company's technology platform integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory process which serves primarily to hospitals and medical institutions. Fulgent Genetics is headquartered in Temple City, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Veeva Systems (VEEV) | United States | $43.014B | 42.92 |
| Tempus AI (TEM) | United States | $11.225B | 0.00 |
| 10x Genomics (TXG) | United States | $9.135B | 0.00 |
| Hinge Health (HNGE) | United States | $7.649B | 73.48 |
| Hims & Hers Health (HIMS) | United States | $6.722B | 0.00 |
| Doximity (DOCS) | United States | $4.704B | 29.00 |
| Heartflow (HTFL) | United States | $4.308B | 0.00 |
| IRhythm Holdings (IRTC) | United States | $3.782B | 249.39 |
| Clover Health Investments (CLOV) | United States | $2.709B | 0.00 |
| Privia Health (PRVA) | United States | $2.667B | 99.43 |
| Inspire Medical Systems (INSP) | United States | $2.149B | 32.74 |
| Butterfly Network (BFLY) | United States | $1.973B | 0.00 |
| Schrodinger (SDGR) | United States | $1.532B | 0.00 |
| Omnicell (OMCL) | United States | $1.524B | 21.76 |
| Azenta (AZTA) | United States | $1.404B | 76.29 |
| Enovis (ENOV) | United States | $1.051B | 5.44 |
| Talkspace (TALK) | United States | $0.879B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.659B | 0.00 |
| Phreesia (PHR) | United States | $0.647B | 34.73 |
| Claritev (CTEV) | United States | $0.618B | 0.00 |
| Veradigm (MDRX) | United States | $0.593B | 0.00 |
| Evolent Health (EVH) | United States | $0.464B | 0.00 |
| Carlsmed (CARL) | United States | $0.419B | 0.00 |
| Senseonics Holdings (SENS) | United States | $0.370B | 0.00 |
| CapsoVision (CV) | United States | $0.326B | 0.00 |
| Standard BioTools (LAB) | United States | $0.273B | 0.00 |
| American Well (AMWL) | United States | $0.230B | 0.00 |
| KORU Medical Systems (KRMD) | United States | $0.144B | 0.00 |
| Health Catalyst (HCAT) | United States | $0.137B | 0.00 |
| Insight Molecular Diagnostics (IMDX) | United States | $0.132B | 0.00 |
| CareCloud (CCLD) | United States | $0.089B | 6.53 |
| Pulmonx (LUNG) | United States | $0.085B | 0.00 |
| Zepp Health (ZEPP) | Netherlands | $0.065B | 0.00 |
| Nyxoah SA (NYXH) | Belgium | $0.062B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.060B | 0.00 |
| Outset Medical (OM) | United States | $0.059B | 0.00 |
| EUDA Health Holdings (EUDA) | Singapore | $0.050B | 0.00 |
| Precipio (PRPO) | United States | $0.049B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.035B | 0.00 |
| 111 (YI) | China | $0.031B | 0.00 |
| Evaxion - (EVAX) | Denmark | $0.026B | 0.00 |
| HeartBeam (BEAT) | United States | $0.023B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.020B | 0.00 |
| HeartSciences (HSCS) | United States | $0.014B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.011B | 0.00 |
| Lunai Bioworks (LNAI) | United States | $0.010B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.009B | 0.00 |
| ITonic Holdings (ITOC) | China | $0.005B | 0.00 |
| DataMeds AI (MEDS) | United States | $0.003B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.003B | 0.00 |
| PROFUSA (PFSA) | United States | $0.002B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.001B | 0.00 |
| Zhongchao (ZCMD) | China | $0.001B | 0.00 |
| TruBridge (TBRG) | United States | $0.000B | 0.00 |